跳至主要内容
临床试验/NL-OMON46331
NL-OMON46331已完成4 期

Prospective longitudinal outcome study assessing the use of BonAlive bioactive glass for attaining eradication of osteomyelitis and stimulation of bone healing in patients requiring surgery in osteomyelitic bone defects. - BonAlive HRpQCT study

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Patients eligible for inclusion in this study are scheduled to undergo osteomyelitis debridement surgery combined with implantation of BonAlive bioactive glass at MUMC+. ;
  • Subjects meeting all of the following criteria will be included in the study.;1. Patients with chronic (>12 weeks) osteomyelitis located in the distal tibia, distal fibula, ankle or foot. Or located in de distal radius, distal ulna, wrist or hand.
  • 2. Patients who are scheduled to undergo osteomyelitis debridement surgery combined with implantation of BonAlive bioactive glass at MUMC+.
  • 3. Patients that have normal contralateral bone, which will be used as an internal control.
  • 4. Patients who accepted and signed the ethics committee approved informed consent before the first HR-pQCT scan.
  • 5. Male and non-pregnant female patients between 18-70 years of age.
  • 6. Patients who are physically and mentally able and willing to comply with the regulations of this study.
  • 7. Patient can read and understand the Dutch language.

排除标准

  • Subjects meeting any of the following criteria will be excluded from the study.;1. Patients who are unwilling to cooperate with the study protocol and follow-up schedule.
  • 2. Patients with chronic osteomyelitis associated with fracture in need of osteosynthesis surgery
  • 3. Patients who, as judged by the surgeon, are mentally incompetent or are likely to be non-compliant with the prescribed post-operative routine and follow-up evaluation schedule.
  • 4. Obese patients where obesity is severe enough to affect subject*s ability to perform activities of daily living (body mass index, kg/m2 > 40)
  • 5. Patients with malignancy - active malignancy within last 1 year
  • 6. Patients known with a diagnosed systemic disease that would affect the subject*s welfare or overall outcome of the study (severe osteoporosis requiring medication, Paget*s disease, renal osteodystrophy, hypercalcaemia) or is immunologically suppressed, or receiving steroids in excess of physiologic dose.
  • 7. Patients with systemic or metabolic disorders leading to progressive bone deterioration.
  • 8. Has received drugs that may interfere with bone metabolism within two weeks prior to the planned surgery date (e.g., steroids or methotrexate) excluding routine perioperative, non-steroidal anti-inflammatory drugs.
  • 9. Patients with a known sensitivity to, specific antibiotics or radiation.
  • 10. Patients under age of 18 and above age of 70
  • 11. Females who wish to become pregnant before, during or after (up to two years) the course of their treatment.

研究者

发起方
Medisch Universitair Ziekenhuis Maastricht

相似试验

Prospective longitudinal outcome study assessing the... | 临床试验